Geron (NASDAQ:GERN) Shares Gap Down – Time to Sell?

Geron Corporation (NASDAQ:GERN)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $1.95, but opened at $1.68. Geron shares last traded at $1.7450, with a volume of 9,700,122 shares traded.

Geron News Summary

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RyTELO commercial momentum — Geron reported RYTELO net product revenue of $48.0M in Q4 and $183.6M for full‑year 2025, with RYTELO demand up 9% sequentially and ~150 new ordering accounts added in Q4, supporting continued top‑line growth. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Positive Sentiment: 2026 revenue guidance reiterated — Management reiterated 2026 RYTELO net product revenue guidance of $220M–$240M, indicating confidence in commercial outlook and providing a measurable growth target for investors. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Neutral Sentiment: Cash runway and cost discipline — Geron ended 2025 with about $401M in cash and marketable securities and reported 2025 operating expense of ~$255M (within prior guidance); management says current resources plus anticipated U.S. RYTELO sales should fund foreseeable needs, but the cash decline from 2024 is notable. Geron Corporation Reports $184 Million in RYTELO® Revenue for 2025 and Provides 2026 Financial Guidance
• Neutral Sentiment: Upcoming catalysts — Management flagged mid‑2026 milestones (IMpactMF interim analysis, initial real‑world trials in LR‑MDS) and scheduled investor presentations (TD Cowen, Barclays) that could move sentiment if results/data surprise. Geron Plans to Present at Upcoming Investor Conferences
• Negative Sentiment: Quarterly loss and perceived miss — The company reported a Q4 net loss of $31.1M and EPS roughly in line with consensus (‑$0.03), but some investors/analysts viewed the results and accompanying metrics as a miss versus expectations, contributing to selling pressure. Geron falls as Q4 results miss expectations
• Negative Sentiment: Restructuring and expense execution — Geron recorded $17M of restructuring charges after cutting ~1/3 of its workforce; SG&A rose as the company invested in sales/marketing. Combined with the cash decline from ~$503M to ~$401M, investors are focused on near‑term cash burn and execution risks. Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Negative Sentiment: Analyst reactions and valuation pressure — Some analyst coverage has been cautious (e.g., TD Cowen trimmed its price target earlier), and recent commentary about valuation vs. volatility has kept trading active and pressure on the shares. Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT

Analyst Upgrades and Downgrades

A number of analysts have weighed in on GERN shares. HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research report on Thursday, January 29th. UBS Group reissued a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. Finally, Needham & Company LLC reduced their price objective on shares of Geron from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $2.75.

Geron Price Performance

The firm has a market cap of $1.06 billion, a P/E ratio of -13.79 and a beta of 0.62. The stock’s 50-day moving average is $1.46 and its 200-day moving average is $1.35. The company has a quick ratio of 4.87, a current ratio of 5.96 and a debt-to-equity ratio of 0.48.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). Geron had a negative net margin of 43.61% and a negative return on equity of 29.63%. As a group, equities analysts anticipate that Geron Corporation will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Geron

A number of hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Geron by 2.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock worth $627,000 after buying an additional 8,123 shares in the last quarter. E Fund Management Co. Ltd. grew its position in Geron by 12.0% during the 2nd quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 9,849 shares during the last quarter. LCM Capital Management Inc grew its holdings in shares of Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 10,000 shares during the last quarter. Velan Capital Investment Management LP grew its holdings in shares of Geron by 14.3% during the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Savant Capital LLC increased its stake in shares of Geron by 73.8% in the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 11,074 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.